Никотинел 7 mg/ 24 h трансдермални пластири х 7 България - български - Изпълнителна агенция по лекарствата

Никотинел 7 mg/ 24 h трансдермални пластири х 7

novartis consumer health gmbh - Никотинът -

Никотинел 14 mg/24 h трансдермални пластири х 7 България - български - Изпълнителна агенция по лекарствата

Никотинел 14 mg/24 h трансдермални пластири х 7

novartis consumer health gmbh - Никотинът -

Никотинел 21 mg/24 h трансдермални пластири х 7 България - български - Изпълнителна агенция по лекарствата

Никотинел 21 mg/24 h трансдермални пластири х 7

novartis consumer health gmbh - Никотинът -

Blincyto Европейски съюз - български - EMA (European Medicines Agency)

blincyto

amgen europe b.v. - blinatumomab - Прекурсорна клетъчна лимфобластна левкемия-лимфом - Антинеопластични средства - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.

Inlyta Европейски съюз - български - EMA (European Medicines Agency)

inlyta

pfizer europe ma eeig  - акситиниб - Карцином, бъбречна клетка - Инхибитори на протеинкиназы - inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc) after failure of prior treatment with sunitinib or a cytokine.

Carvykti Европейски съюз - български - EMA (European Medicines Agency)

carvykti

janssen-cilag international nv - ciltacabtagene autoleucel - Множествена миелома - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Kimmtrak Европейски съюз - български - EMA (European Medicines Agency)

kimmtrak

immunocore ireland limited - tebentafusp - uveal neoplasms - Антинеопластични средства - kimmtrak is indicated as monotherapy for the treatment of human leukocyte antigen (hla)-a*02:01-positive adult patients with unresectable or metastatic uveal melanoma.

Somazina  100 mg/ml oral solution България - български - Изпълнителна агенция по лекарствата

somazina  100 mg/ml oral solution

ferrer internacional s.a. - Цитиколин - 100 mg/ml oral solution

Somazina  1000 mg/ 4ml solution for injection България - български - Изпълнителна агенция по лекарствата

somazina  1000 mg/ 4ml solution for injection

ferrer internacional s.a. - Цитиколин - 1000 mg/ 4ml solution for injection

Somazina  500 mg/ 4ml solution for injection България - български - Изпълнителна агенция по лекарствата

somazina  500 mg/ 4ml solution for injection

ferrer internacional s.a. - Цитиколин - 500 mg/ 4ml solution for injection